ESR1 and neoplasm: Already, it has been shown that SI-2, can be effectively combined with the selective estrogen receptor degrader (SERD) AZD9496 to inhibit tumor growth in an ERα Y537S mutant patient-derived xenograft (PDX) animal model19.